Gerresheimer AG
XETRA:GXI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
70.15
110.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gerresheimer AG
Income from Continuing Operations
Gerresheimer AG
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Gerresheimer AG
XETRA:GXI
|
Income from Continuing Operations
€116.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
4%
|
||
E
|
Evotec SE
XETRA:EVT
|
Income from Continuing Operations
-€171.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Income from Continuing Operations
€151.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Gerresheimer AG
Glance View
Gerresheimer AG manufactures and supplies glass and plastic products for the pharmaceutical and healthcare industry. The company is headquartered in Dusseldorf, Nordrhein-Westfalen and currently employs 10,625 full-time employees. The company went IPO on 2007-06-11. The company operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The firm operates approximately 40 production facilities in Europe, North America, South America and Asia.
See Also
What is Gerresheimer AG's Income from Continuing Operations?
Income from Continuing Operations
116.3m
EUR
Based on the financial report for Aug 31, 2024, Gerresheimer AG's Income from Continuing Operations amounts to 116.3m EUR.
What is Gerresheimer AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
4%
Over the last year, the Income from Continuing Operations growth was 3%. The average annual Income from Continuing Operations growth rates for Gerresheimer AG have been 9% over the past three years , -10% over the past five years , and 4% over the past ten years .